The stock is a binary catalyst play on OCS-01 DIAMOND Phase 3 data in June 2026. With $277.6M cash runway into 2H 2029, the company is well-funded through multiple readouts. Monitor the OCS-01 topline results closely — positive data would de-risk the lead asset and enable NDA submission in Q4 2026, while negative results would significantly impair the pipeline's value. The FDA SPA for Privosegtor PIONEER-1 is a positive regulatory milestone but does not change the binary nature of near-term catalysts.
Price Chart
Executive Summary
Oculis reported Q1 2026 results with a net loss of CHF 28.9 million ($36.8M), improved from CHF 33.2 million ($36.9M) in Q1 2025, driven by lower non-cash warrant liability losses and favorable FX. The pre-revenue biotech ended the quarter with $277.6M in cash, providing runway into 2H 2029. Key catalysts are on track: OCS-01 DIAMOND Phase 3 topline data expected June 2026, Licaminlimab PREDICT-1 data around year-end 2026, and Privosegtor received FDA SPA agreement for PIONEER-1 in May 2026. Operating expenses rose 8% YoY to CHF 21.9M, with G&A up 44% due to higher share-based compensation.
Key Facts
- Net loss of CHF 28.9 million ($36.8M) for Q1 2026 vs CHF 33.2 million ($36.9M) in Q1 2025
- Cash, cash equivalents and short-term investments of $277.6 million (CHF 222.0M) as of March 31, 2026
- Cash runway into 2H 2029
- OCS-01 DIAMOND Phase 3 trials completed last patient visit in April 2026; topline results expected June 2026
- Privosegtor received FDA Special Protocol Assessment (SPA) agreement for PIONEER-1 in May 2026
- Licaminlimab PREDICT-1 Phase 2/3 trial topline results expected around year-end 2026
- R&D expenses decreased 5% YoY to CHF 14.0M, driven by DIAMOND trial completion
- G&A expenses increased 44% YoY to CHF 7.9M, primarily from higher share-based compensation
- Raised CHF 22.4M ($28.8M) gross from ATM program in Q1 2026
- No revenue from product sales; pre-revenue clinical-stage biopharmaceutical company
Financial Impact
Net loss improved by CHF 4.4M YoY to CHF 28.9M; cash position increased by CHF 9.0M from year-end 2025 to CHF 222.0M
Risk Factors
- OCS-01 DIAMOND Phase 3 topline data in June 2026 is a binary event — failure would eliminate the lead pipeline asset
- Pre-revenue company with no approved products; continued operating losses expected
- Potential dilution from $100M ATM program and future equity raises
- Licaminlimab and Privosegtor are still in early-to-mid stage clinical development with significant execution risk
- Warrant liabilities of CHF 20.5M create non-cash earnings volatility tied to stock price movements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-216741 |
| Document: ocs-ex99_2.htm | 0001193125-26-216741 |
| Document: ocs-ex99_3.htm | 0001193125-26-216741 |
| Document: q1_2026_6-k_fs_mda_pr.htm | 0001193125-26-216741 |
| Document: 0001193125-26-216741-index-headers.html | 0001193125-26-216741 |
| Document: 0001193125-26-216741-index.html | 0001193125-26-216741 |
| Document: 0001193125-26-216741.txt | 0001193125-26-216741 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 11, 2026 24w ago | 6-K | $16.43 | awaiting T+60 | — | — |
Apr 21, 2026 27w ago | 6-K | $16.43 $4.60 | ▼ −72.03% | ▼ −76.81% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers